

Data Sheet

NAME:	vBD3
REPOSITORY REFERENCE:	ARP2110
PRESENTATION:	100ul Vaccinia virus lysate from RK13 cells. 3.4 x 10 ⁸ pfu/ml.
DESCRIPTION:	Contains the HIV-1 89.6 gp160 gene under control of the vaccinia virus early/late promoter. The 89.6 env gene was cloned into pSC59 and then introduced into vaccinia virus strain WR by homologous recombination.
SPECIAL CHARACTERISTICS:	Cells infected with vBD3 express env glycoprotein from the dual trophic HIV-1 primary isolate 89.6, which uses both CXCR4 and CCR5, and well as a number of other chemokine co-receptors for entry. The gp160 is expressed on the surface of infected cells, and supports cell-cell fusion with CD4+ cells. Can also be used to generate gp120 from supernatants of infected cells.
STERILITY:	Negative for Bacteria, fungi and mycoplasma.
RECOMMENDED STORAGE:	-70°C
SOURCE:	Dr Ronald Collman and Dr Robert Doms, Courtesy of the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.

REFERENCE:

Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. A dual-trophic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. *Cell* **85**: 1149-1158, 1996.

Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, Srinivasan A. An unusual macrophage-trophic and highly cytopathic strain of human immunodeficiency Virus type 1. *J. Virol* **66**: 7517-7521, 1992.

ACKNOWLEDGEMENTS:

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)